Literature DB >> 16893923

Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis.

Gabriel Nussbaum1, Alexandra Zanin-Zhorov, Francisco Quintana, Ofer Lider, Irun R Cohen.   

Abstract

Peptide p277 is a 24-amino acid fragment of the heat shock protein 60 molecule, first discovered to be an antigen for diabetogenic T-cell clones in non-obese diabetic (NOD) mice. Therapeutic vaccination with p277 can arrest the spontaneous diabetogenic process both in NOD mice and in humans associated with a T(h)1 to T(h)2 cytokine shift specific for the autoimmune T cells. We now report that p277 can directly signal human T cells via innate toll-like receptor (TLR)-2, leading to up-regulation of integrin-mediated adhesion to fibronectin, and inhibition of chemotaxis to the chemokine SDF-1alpha in vitro. Resting CD45RA(+) T cells responded to lower concentrations of p277 than resting CD45RO(+) T cells, but activation of CD45RO(+) T cells greatly increased their sensitivity to p277. Mouse T cells, but not macrophages, were also sensitive to the innate effects of peptide p277, and adoptive transfer of diabetes by splenic T cells from NOD mice could be inhibited by p277 treatment before transfer. Thus, T cells do respond innately to p277, and signaling by soluble p277 through TLR2 could contribute to the treatment of type 1 diabetes; p277 may stop the destruction of beta cells by signaling in concert both innate and adaptive receptors on T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893923     DOI: 10.1093/intimm/dxl074

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  13 in total

Review 1.  T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.

Authors:  Jeffrey Babad; Ari Geliebter; Teresa P DiLorenzo
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

Review 2.  Caught with their PAMPs down? The extracellular signalling actions of molecular chaperones are not due to microbial contaminants.

Authors:  Brian Henderson; Stuart K Calderwood; Anthony R M Coates; Irun Cohen; Willem van Eden; Thomas Lehner; A Graham Pockley
Journal:  Cell Stress Chaperones       Date:  2010-03       Impact factor: 3.667

Review 3.  Immune intervention in type 1 diabetes.

Authors:  Aaron W Michels; George S Eisenbarth
Journal:  Semin Immunol       Date:  2011-08-17       Impact factor: 11.130

4.  Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition.

Authors:  D-H Kim; J-C Lee; M-K Lee; K-W Kim; M-S Lee
Journal:  Diabetologia       Date:  2012-09-27       Impact factor: 10.122

Review 5.  Immunotherapy of type 1 diabetes: where are we and where should we be going?

Authors:  Xunrong Luo; Kevan C Herold; Stephen D Miller
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

Review 6.  Antigen-specific therapeutic approaches in Type 1 diabetes.

Authors:  Xavier Clemente-Casares; Sue Tsai; Carol Huang; Pere Santamaria
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

Review 7.  Heat shock proteins with an emphasis on HSP 60.

Authors:  Javid Ahmad Malik; Rafiq Lone
Journal:  Mol Biol Rep       Date:  2021-09-08       Impact factor: 2.316

Review 8.  Innate immunity in diabetes and diabetic nephropathy.

Authors:  Jun Wada; Hirofumi Makino
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

9.  Mycobacterium tuberculosis heat-shock protein 70 impairs maturation of dendritic cells from bone marrow precursors, induces interleukin-10 production and inhibits T-cell proliferation in vitro.

Authors:  Adriana Motta; Carla Schmitz; Luiz Rodrigues; Flávia Ribeiro; Cesar Teixeira; Thiago Detanico; Carla Bonan; Heather Zwickey; Cristina Bonorino
Journal:  Immunology       Date:  2007-03-07       Impact factor: 7.397

10.  The Legionella pneumophila Chaperonin - An Unusual Multifunctional Protein in Unusual Locations.

Authors:  Rafael A Garduño; Audrey Chong; Gheyath K Nasrallah; David S Allan
Journal:  Front Microbiol       Date:  2011-06-10       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.